Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2020-06-12 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天津天士力医药营销集团股份有限公司2018年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled "2018年度审计报告" which translates to "2018 Annual Audit Report". It contains detailed audit opinions, financial statements including consolidated and parent company balance sheets, income statements, cash flow statements, and notes to the financial statements. The document includes auditor's responsibilities, management's responsibilities, and detailed audit procedures for key audit matters such as accounts receivable impairment and revenue recognition. The length is substantial (15,000 characters) and contains the full audit report and financial statements, not just an announcement or certification. Therefore, this document is a standalone Audit Report containing the audit opinion and related financial information, not the full Annual Report or other filings.
2020-06-12 Chinese
关于子公司作为基石投资者参与永泰生物制药有限公司香港首次公开发行暨与关联人形成共同投资关系的关联交易公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by TianShiLi Pharmaceutical Group Co., Ltd. regarding its subsidiary acting as a cornerstone investor in the initial public offering (IPO) of YongTai Biopharmaceutical Co., Ltd. on the Hong Kong Stock Exchange. It details the investment amount, the relationship with related parties, the approval process by the board of directors, and risk disclosures. The document is structured as a formal announcement of a related-party transaction and investment activity, not a financial report or detailed financial statements. It does not contain quarterly or annual financial results, audit opinions, or management discussion and analysis. The document is over 6,000 characters and provides comprehensive disclosure about the transaction, consistent with a capital/financing update or related-party transaction announcement. Given the content focuses on investment participation and related-party transaction disclosure, the most appropriate classification is Capital/Financing Update (CAP).
2020-06-12 Chinese
关于本次交易摊薄即期回报的风险提示及填补措施的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by TianShiLi Pharmaceutical Group Co., Ltd. regarding a major asset restructuring transaction involving the sale of a subsidiary's equity. It discusses the risk of dilution of immediate earnings per share due to the transaction and outlines measures to mitigate this dilution. The document includes detailed commitments from the company's board and controlling shareholders to protect investor interests and comply with regulatory requirements. It references regulatory guidelines related to protecting minority investors and major asset restructuring. The document is not a full financial report, audit report, or earnings release but rather a regulatory announcement about the transaction's impact on earnings and the company's response measures. It is a formal disclosure related to a capital transaction and its effects, fitting the category of Capital/Financing Update (CAP). The document length is 2452 characters, which is relatively short but contains substantive information about the transaction and its financial impact, not merely a notice or report publication announcement. Therefore, the best classification is CAP with high confidence.
2020-06-12 Chinese
内蒙古建中律师事务所关于公司本次交易相关内幕知情人买卖上市公司股票情况的自查报告的核查意见
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the self-inspection report on insider trading related to a major asset restructuring transaction by a listed company. It focuses on the verification of insider trading activities during a specific period related to the transaction. The document is not a financial report, earnings release, or management discussion. It is a legal proceeding-related document providing a verification opinion on compliance with securities laws and insider trading regulations. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length is 2429 characters, which is too short to be a full report like an Annual Report or Interim Report, and it contains substantive legal content rather than just an announcement or certification, so it is not RNS or RPA.
2020-06-12 Chinese
第七届董事会第16次会议相关事项的事前认可函
Regulatory Filings Classification · 95% confidence The document is a letter of prior approval from independent directors regarding matters to be discussed at the company's 7th board meeting, specifically about a major asset sale and related transactions. It references relevant laws and regulations, and provides independent directors' opinions on the proposed transactions. The document is not a full report but a formal opinion or certification related to board decisions. It does not contain financial statements or detailed financial analysis. It is not an announcement of a report publication but a regulatory compliance document related to board matters. Therefore, it fits best under Regulatory Filings (RNS) as it is a formal regulatory compliance document and independent directors' approval letter rather than a full management report or audit report.
2020-06-12 Chinese
国信证券股份有限公司关于公司本次交易产业政策和交易类型之独立财务顾问核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Verification Opinion" issued by Guosen Securities Co., Ltd. regarding a major asset sale by Tianshili Pharmaceutical Group Co., Ltd. It references regulatory frameworks from the China Securities Regulatory Commission (CSRC) and Shanghai Stock Exchange related to merger and acquisition review processes. The content focuses on the verification of the transaction type, industry classification, and compliance with relevant policies. It does not contain financial statements or detailed financial performance data but rather an advisory opinion on the transaction's regulatory and policy compliance. The document length is 3190 characters, which is relatively short and consistent with an advisory or opinion letter rather than a full financial report. This type of document fits the category of a specialized audit or advisory report related to a transaction, which aligns best with the "Audit Report / Information (AR)" category rather than a full Annual Report or other categories. Therefore, the classification is AR with high confidence. H1 2020
2020-06-12 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.